Selumetinib Continues to Show Promise in Children with NF1

In a phase 2 clinical trial, the investigational drug selumetinib shrank tumors in some children with the genetic syndrome neurofibromatosis type 1 (NF1). The tumors, called neurofibromas, can cause pain, difficulty breathing or walking, and disfigurement.

Cancer Currents: An NCI Cancer Research Blog